The 5-year survival rate was 18.2 % ( 95 % CI , 13.6 % to 23.4 % ) for patients treated with ipilimumab plus dacarbazine versus 8.8 % ( 95 % CI , 5.7 % to 12.8 % ) for patients treated with placebo plus dacarbazine ( P = .002 ) .